Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis (ES29)
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis
Search results
12 results
-
-
Antimicrobial prescribing: imipenem with cilastatin and relebactam (ES30)
Summary of the evidence on antimicrobial prescribing: imipenem with cilastatin and relebactam
-
Antimicrobial prescribing: cefiderocol (ES31)
Summary of the evidence on antimicrobial prescribing: cefiderocol
-
Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections (ES32)
Summary of the evidence on antimicrobial prescribing: delafloxacin
-
COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 (ES24)
ES24 . Key messages The content of this evidence review was up-to-date
-
COVID-19 rapid evidence summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES25)
ES25 . Key messages The content of this evidence review was up-to-date on 20 April 2020. See summaries of product characteristics
-
COVID 19 rapid evidence summary: Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis (ES26)
ES26 . Key messages The content of this evidence review was up-to-date on 13 May 2020. See summaries of product characteristics
-
COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES23)
ES23 . Key messages The content of this evidence review was up-to-date
-
COVID-19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 (ES27)
ES27 . Key messages The content of this evidence review was up-to-date on 4 June 2020. See summaries of product characteristics
-
COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)
ES33 Product overview The content of this evidence summary was up to date in January 2021. See summaries of product characteristics
-
COVID-19 rapid evidence summary: Sarilumab for COVID-19 (ES34)
ES34 Product overview The content of this evidence summary was up to date in January 2021. See summaries of product characteristics
-
COVID-19 rapid evidence summary: vitamin D for COVID-19 (ES28)
This evidence summary has been updated and replaced by the COVID-19 rapid guideline on vitamin D (NG187).